Pancreatic Tumours and Radiation Therapy: What the DNA Says

Recent research examined the DNA of 40 pancreatic tumours from 32 patients treated with Peptide Receptor Radionuclide Therapy (PRRT). The goal was to identify genetic predictors of treatment success and detect new mutations post‑therapy.

Key Genetic Findings

• Common Hits
• ~33 % had alterations in the MEN1 gene.
• Nearly 50 % carried mutations in ATRX or DAXX.

• 33 % displayed large chromosome copy‑number changes.

• Rare Fusion
• A PSIP1–TBL1X gene fusion appeared in four tumours; its significance remains unclear.

Clinical Outcomes

• Disease Control
• Using size‑based criteria and imaging, 88 % of patients achieved disease control after PRRT.
• No specific mutation correlated with longer or shorter progression‑free intervals.

Pre‑ vs. Post‑PRRT Mutational Landscape

• The total mutation burden did not increase significantly after treatment.
• No new driver mutations emerged that would explain a shift to more aggressive disease.
• ID8: A small insertion/deletion pattern (ID8) rose markedly post‑PRRT, linked to the non‑homologous end joining DNA repair pathway. This suggests tumour cells preferentially use this mechanism to mend therapy‑induced damage.

Takeaway

The study found no clear genetic markers predicting PRRT efficacy or evidence of widespread DNA damage from the treatment. However, it illuminated how tumour cells repair radiation‑induced lesions, offering insights that could inform future therapeutic strategies.